ALLO Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipe…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 CLLS Stock Heads For 14-Month Low After 40% Rout: Citizens Flags Delayed Cellectis Catalysts After Cancer Pipeline Pivot Cellectis received a downgrade after pivoting to cardiovascular diseases therapy from a type of cancer therapy | ||
 Allogene Therapeutics (ALLO) Down 11.1% Since Last Earnings Report: Can It Rebound? Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. | ||
 Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts Wall Street analysts believe that a more cautious approach to manufacturing, study enrollment and side effect management could help developers avoid future safety hazards. | ||
 Allogene (ALLO) Q2 2026 Earnings Call Transcript Cema-cel hit 58.3% MRD negativity in ALPHA3 with zero treatment hospitalizations. | ||
 Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year? Here is how Allogene Therapeutics (ALLO) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year. | ||
 Allogene Therapeutics' Q2 Earnings Beat Estimates on Lower R&D Costs ALLO narrows its Q2 loss as R&D costs fall, while a stronger cash position extends its runway into 2029. | ||
Allogene Therapeutics Remains Attractive Given Valuation, Clinical Strategy, RBC Says Allogene Therapeutics (ALLO) remains attractive given its undemanding valuation and differentiated c | ||
 Allogene Therapeutics, Inc. Q2 2026 Earnings Call Summary Moby summary of Allogene Therapeutics, Inc.'s Q2 2026 earnings call | ||
Allogene Therapeutics Inc (ALLO) (Q2 2026) Earnings Call Highlights: RMAT Designation and Rapid ... Allogene Therapeutics Inc (ALLO) advances its allogeneic CAR-T pipeline with key regulatory milestones and strong trial momentum, while navigating solid tumor challenges and competitive pressures. | ||
 Allogene Therapeutics Q2 Earnings Call Highlights Allogene Therapeutics (NASDAQ:ALLO) outlined progress across its clinical pipeline during its second-quarter 2026 conference call, highlighting expanded enrollment infrastructure for its pivotal ALPHA3 lymphoma study, recent FDA designations for cema-cel, published renal cell carcinoma data for ALLO | ||